Contineum Therapeutics, Inc. Class A Common Stock (CTNM) - Net Assets
Based on the latest financial reports, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has net assets worth $239.66 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($250.37 Million) and total liabilities ($10.71 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See CTNM net asset quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $239.66 Million |
| % of Total Assets | 95.72% |
| Annual Growth Rate | 43.48% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 130.62 |
Contineum Therapeutics, Inc. Class A Common Stock - Net Assets Trend (2021–2025)
This chart illustrates how Contineum Therapeutics, Inc. Class A Common Stock's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see CTNM company net worth.
Annual Net Assets for Contineum Therapeutics, Inc. Class A Common Stock (2021–2025)
The table below shows the annual net assets of Contineum Therapeutics, Inc. Class A Common Stock from 2021 to 2025. Also explore Contineum Therapeutics, Inc. Class A Com equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $260.99 Million | +31.77% |
| 2024-12-31 | $198.07 Million | +391.55% |
| 2023-12-31 | $-67.94 Million | -273.00% |
| 2022-12-31 | $39.27 Million | -36.24% |
| 2021-12-31 | $61.59 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Contineum Therapeutics, Inc. Class A Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10376900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $37.00K | 0.01% |
| Other Comprehensive Income | $260.00K | 0.10% |
| Other Components | $438.07 Million | 167.85% |
| Total Equity | $260.99 Million | 100.00% |
Contineum Therapeutics, Inc. Class A Common Stock Competitors by Market Cap
The table below lists competitors of Contineum Therapeutics, Inc. Class A Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Liuzhou Liangmianzhen Co Ltd
SHG:600249
|
$435.41 Million |
|
Xinjiang Talimu Agriculture Development Co Ltd
SHG:600359
|
$435.45 Million |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
$435.56 Million |
|
Sino-Argi Leading Biosciences
SHG:603970
|
$435.82 Million |
|
Plastika Kritis S.A.
AT:PLAKR
|
$435.33 Million |
|
Actron Technology
TWO:8255
|
$435.18 Million |
|
Taiwan Navigation Co Ltd
TW:2617
|
$435.17 Million |
|
Hibiscus Petroleum BHD
KLSE:5199
|
$435.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Contineum Therapeutics, Inc. Class A Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 198,066,000 to 260,989,000, a change of 62,923,000 (31.8%).
- Net loss of 59,978,000 reduced equity.
- New share issuances of 112,255,000 increased equity.
- Other comprehensive income increased equity by 189,000.
- Other factors increased equity by 10,457,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-59.98 Million | -22.98% |
| Share Issuances | $112.25 Million | +43.01% |
| Other Comprehensive Income | $189.00K | +0.07% |
| Other Changes | $10.46 Million | +4.01% |
| Total Change | $- | 31.77% |
Book Value vs Market Value Analysis
This analysis compares Contineum Therapeutics, Inc. Class A Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.40x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.39x to 1.40x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $2.45 | $13.21 | x |
| 2022-12-31 | $1.56 | $13.21 | x |
| 2023-12-31 | $-2.70 | $13.21 | x |
| 2024-12-31 | $7.66 | $13.21 | x |
| 2025-12-31 | $9.42 | $13.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Contineum Therapeutics, Inc. Class A Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -22.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.06x
- Recent ROE (-22.98%) is above the historical average (-30.63%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -47.09% | 0.00% | 0.00x | 1.14x | $-35.16 Million |
| 2022 | -61.76% | 0.00% | 0.00x | 1.29x | $-28.18 Million |
| 2023 | 0.00% | 45.44% | 0.38x | 0.00x | $29.51 Million |
| 2024 | -21.34% | 0.00% | 0.00x | 1.07x | $-62.06 Million |
| 2025 | -22.98% | 0.00% | 0.00x | 1.06x | $-86.08 Million |
Industry Comparison
This section compares Contineum Therapeutics, Inc. Class A Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Contineum Therapeutics, Inc. Class A Common Stock (CTNM) | $239.66 Million | -47.09% | 0.04x | $435.38 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibr… Read more